13 completed, 9 terminated, 4 active not recruiting, 3 recruiting. 30 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 13, Terminated 9, Active not recruiting 4, Recruiting 3, Withdrawn 1 |
| Phase 2 | 13 | Completed 6, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients Physical examination, Electrocardiogram, SF-36 questionnaire - SLE, Lupus | Phase 1 | Recruiting | LiveKidney.Bio | 10 | 2025-01-07 | 2025-09-11 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra - Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2023-04-07 | 2026-10-06 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Obinutuzumab, Prednisone, Lenalidomide - Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2022-04-19 | 2026-01-08 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma LMB-100, ipilimumab, Diphenhydramine - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2021-06-11 | 2024-02-02 |
| Study of Codivir in Patients With COVID-19 Covidir injections, One Step Test, IgM and IgG dosage - Covid19 | Phase 1 | Completed | Code Pharma | 12 | 2021-03-29 | 2021-11-02 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers PRGN-2009, M7824, EKG - HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2020-08-11 | 2026-08-18 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Cyclophosphamide, Fludarabine, Aldesleukin - Gastrointestinal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-05-16 | 2026-05-19 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Zolpidem, ECG - Prostatic Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2019-01-22 | 2026-06-26 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers M7824, Topotecan, Temozolomide - Carcinoma, Small Cell, Lung Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2018-09-11 | 2025-05-09 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Durvalumab, Vicineum, Acetaminophen - Urinary Bladder Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2018-06-07 | 2026-10-27 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
Showing 20 of 30. Sign in to see all of them.
Myelodysplastic Syndromes (4) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Prostatic Neoplasms (3) · Burkitt Lymphoma (2) · COVID-19 (2) · Carcinoma in Situ (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, B-Cell (2) · Neoplasms (2) · Rectal Neoplasms (2) · Small Cell Lung Carcinoma (2) · Anus Neoplasms (1) · Atrial Fibrillation (1)
National Cancer Institute (NCI) (22) · Code Pharma (1) · LiveKidney.Bio (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Thomas Jefferson University (1) · Yael P Mosse (1)
United States (28) · Brazil (1)
Anish Thomas, M.D. (2) · Najla El Jurdi, M.D. (2) · Scott M Norberg, D.O. (2) · Alain Mina, M.D. (1) · Charalampos Floudas, M.D. (1) · Chetan Jeurkar, DO (1) · Christopher J Melani, M.D. (1) · Ciprian Catana, PhD (1) · Eynat Finkelshtein (1) · James C Yang, M.D. (1) · James L Gulley, M.D. (1) · Jibran Ahmed, M.D. (1) · Joerg Herrmann, MD (1) · John M Maris, MD (1) · Kieron Dunleavy (1)
PMID 42820295, PMID 30227893, PMID 32508818, PMID 32897402, PMID 33558725, PMID 33602696, PMID 34656469, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 37682953, PMID 37882668, PMID 37975597, PMID 38376944, PMID 40116923, PMID 40331908, PMID 41425223, PMID 41779512, PMID 42248607, PMID 42498485
2015 (1), P30CA051008 (1), R01HL109448 (1)